Related Experiment Video
Updated: Jul 5, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
Acute interstitial nephritis associated with etanercept
Toshiro Sugimoto1, Mako Yasuda, Masayoshi Sakaguchi
1Department of Internal Medicine, Shiga University of Medical Science, Seta, Otsu, Shiga 520-2192, Japan. toshiro@belle.shiga-med.ac.jp
A patient with rheumatoid arthritis developed acute interstitial nephritis after receiving etanercept, a tumor necrosis factor alpha inhibitor. This case highlights a potential adverse effect of this biologic therapy.
Area of Science:
- Rheumatology
- Nephrology
- Immunology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- Biologic agents, such as tumor necrosis factor alpha (TNF-α) inhibitors, are used to treat RA.
- Etanercept is a common TNF-α inhibitor.
Observation:
- An adult RA patient developed acute interstitial nephritis (AIN).
- The patient was treated with etanercept.
Findings:
- The AIN was temporally associated with etanercept treatment.
- This suggests a potential drug-induced kidney injury.
Implications:
- Clinicians should consider AIN in RA patients on etanercept presenting with renal symptoms.
- Further investigation into TNF-α inhibitors and renal adverse events is warranted.
Related Concept Videos
Acute Kidney Injury II: Pathophysiology
Acute Pyelonephritis I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome I : Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury I: Introduction